ASX:MSBBiotechs
Mesoblast (ASX:MSB) Valuation in Focus After Ryoncil Launch and Pipeline Milestones Unveiled in New York
If you are tracking Mesoblast (ASX:MSB), the company’s latest updates at major healthcare conferences in New York are tough to ignore. Mesoblast grabbed attention with news of a strong first quarter launch for Ryoncil, its FDA-approved therapy for pediatric steroid-refractory acute graft versus host disease (SR-aGvHD). In addition to highlighting early sales and new treatment sites coming online, management revealed plans to expand Ryoncil into additional indications, including adult SR-aGvHD...